AVITA Medical, Inc. Q3 2025 Earnings Recap

RCEL Q3 2025 November 7, 2025

AVITA Medical reported Q3 2025 revenues of approximately $17 million, falling short of expectations due to ongoing reimbursement disruptions, but anticipates renewed demand and adoption for its RECELL product following resolution of payment clarity.

Earnings Per Share Miss

$-0.46 vs $-0.43 est.

-7.0% surprise

Revenue Miss

17062000 vs 26859380 est.

-36.5% surprise

Market Reaction

1-Day +10.88%

5-Day +11.18%

30-Day +5.88%

Key Takeaways

Revenue guidance for the full year adjusted to $70 million to $74 million, down from $76 million to $81 million.
All seven regional Medicare Administrative Contractors have established reimbursement rates for RECELL, enhancing clinician confidence and adoption.
The company is refining its commercial strategies, focusing on approximately 200 key burn centers, representing a $1.3 billion opportunity within the broader $3.5 billion U.S. market.
Recent CE Mark approval for RECELL GO expands access to the technology in Europe, with the first patient treated in Germany.
Management's immediate priorities include revitalizing order momentum, driving consistent product utilization, and finalizing the transition of the commercial organization for improved performance.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RCEL on AllInvestView.